TITLE

Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis

AUTHOR(S)
Gafter-Gvili, Anat; Vidal, Liat; Goldberg, Elad; Leibovici, Leonard; Paul, Mical
PUB. DATE
September 2008
SOURCE
Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p1011
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To compare available antifungal treatments for invasive candidiasis, a leading cause of nosocomial bloodstream infections. METHODS: We performed a systematic review and meta-analysis of randomized controlled trials that compared different antifungal agents for the treatment of candidemia and other forms of invasive candidiasis. Two reviewers independently appraised the quality of trials and extracted data. The primary outcome was all-cause mortality, and secondary outcomes were microbiological failure, treatment failure, and adverse events. Relative risks (RRs) with 95% confidence intervals (CIs) were pooled. RESULTS: Of the 15 Included trials, 9 compared fluconazole with other drugs (amphotericin B, itraconazole, or a combination of fluconazole and amphotericin B), 4 compared echinocandins with other drugs (fluconazole, amphotericin B, liposomal amphotericin B), 1 compared micafungin and caspofungin, and 1 compared amphotericin B plus fluconazole and voriconazole. No difference in mortality was observed with fluconazole vs amphotericin B (RR, 0.92; 95% Cl, 0.72.1.17); however, the rate of microbiological failure increased in the fluconazole arm (RR, 1.52; 95% Cl, 1.12-2.07). Anidulafungin decreased the rate of microbiological failure compared with fluconazole (RR, 0.50; 95% Cl, 0.29-0.86) with fewer adverse events. Caspofungin was comparable to amphotericin B in mortality and efficacy, with fewer adverse events requiring discontinuation (RR, 0.11; 95% Cl, 0.04-0.36). Micafungin was comparable to liposomal amphotericin B in mortality. CONCLUSION: All assessed antifungal agents showed similar efficacy, but the rate of microbiological failure increased with fluconazole vs amphotericin B or anidulafungin. Amphotericin B is associated with a higher rate of adverse events than fluconazole and echinocandins.
ACCESSION #
34205907

 

Related Articles

  • Fluconazole Plus Amphotericin B Combinations Are Not Contraindicated and May Add Benefit for the Treatment of Candidemia. Odds, Frank C. // Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1229 

    Editorial. Presents the views of the author on the combination therapy of fluconazole and amphotericin (Am) B for the treatment of candidemia. Difficulties in the diagnosis of invasive fungal infections; Reference to the study conducted by John H. Rex et al and published in the May 15, 2003...

  • A Randomized and Blinded Multicenter Trial of High-Dose Fluconazole plus Placebo versus Fluconazole plus Amphotericin B as Therapy for Candidemia and Its Consequences in Nonneutropenic Subjects. Rex, John H.; Pappas, Peter G.; Karchmer, Adolf W.; Sobel, Jack; Edwards, John E.; Hadley, Susan; Brass, Corstiaan; Vazquez, Jose A.; Chapman, Stanley W.; Horowitz, Harold W.; Zervos, Marcus; McKinsey, David; Lee, Jeannette; Babinchak, Timothy; Bradsher, Robert W.; Cleary, John D.; Cohen, David M.; Danziger, Larry; Goldman, Mitchell // Clinical Infectious Diseases;5/15/2003, Vol. 36 Issue 10, p1221 

    A randomized, blinded, multicenter trial was conducted to compare fluconazole (800 mg per day) plus placebo with fluconazole plus amphotericin B (AmB) deoxycholate (0.7 mg/kg per day, with the placebo/AmB component given only for the first 5-6 days) as therapy for candidemia due to species other...

  • Worsening of Endogenous Candida albicans Endophthalmitis During Therapy with Intravenous Lipid... Virata, Steven R.; Kylstra, Jan A.; Brown, Justin C.; Wohl, David A.; Cohen, Myron S. // Clinical Infectious Diseases;5/1/1999, Vol. 28 Issue 5, p1177 

    Describes a patient with endogenous Candida albicans endophthalmitis that progressed after intravenous antifungal therapy was changed from fluconazole to lipid complex amphotericin B. Clinical diagnosis; Medical treatment; Efficacy of intravenous amphotericin B in treating C. albicans...

  • In vitro activity of antifungal combinations against Candida albicans biofilms. Tobudic, Selma; Kratzer, Christina; Lassnigg, Andrea; Graninger, Wolfgang; Presterl, Elisabeth // Journal of Antimicrobial Chemotherapy (JAC);Feb2010, Vol. 65 Issue 2, p271 

    Objectives: The aim of the present study was to evaluate the in vitro activity and synergism of the combinations of amphotericin B/caspofungin and amphotericin B/posaconazole against Candida albicans, grown either as planktonic cells or in biofilms.

  • Effects of Antifungal Agents Alone and in Combination Against Candida glabrata Strains Susceptible or Resistant to Fluconazole. Alves, Izabel; Bandeira, Laíssa; Mario, Débora; Denardi, Laura; Neves, Louise; Santurio, Janio; Alves, Sydney // Mycopathologia;Sep2012, Vol. 174 Issue 3, p215 

    The rise of Candida spp. resistant to classic triazole antifungal agents has led to a search for new therapeutic options. Here, we evaluated combinations of antifungals in a checkerboard assay against two groups of Candida glabrata strains: one containing fluconazole-susceptible clinical...

  • The Role of Echinocandins in the Treatment of Invasive Candidiasis. Pappas, Peter C. // Japanese Journal of Medical Mycology;2008 Supplement 1, Vol. 49, p71 

    The article discusses the vital role of antifungal agent echinocandins in treating invasive candidiasis (IC), a fungal disease. Studies found that echinocandins are more effective and safe in the treatment of IC where 70 to 75% of patients were cured than other treatments, including amphotericin...

  • In Vitro Effect of Amphotericin B on Candida albicans, Candida glabrata and Candida parapsilosis Biofilm Formation. Prażyńska, Małgorzata; Gospodarek, Eugenia // Mycopathologia;Feb2014, Vol. 177 Issue 1/2, p19 

    Candida spp. biofilm is considered highly resistant to conventional antifungals. The aim of this study was to investigate the in vitro effect of amphotericin B on Candida spp. biofilms at different stages of maturation. We investigated the activity of amphotericin B against 78 clinical isolates...

  • Fluconazole vs. amphotericin B in the treatment of candidemia.  // American Family Physician;3/1/1995, Vol. 51 Issue 4, p953 

    Highlights the study conducted by Rex et al, published in the November 17, 1994 issue of the `New England Journal of Medicine.' Comparison between amphotericin B and fluconazole, an antifungal agent, in the treatment of systemic candidemia; Etiology of vaginal candidiasis; Common infecting species.

  • Invasive fungal infections. Hope, William; Natarajan, Pavithra; Goodwin, Lynsey // Clinical Medicine;Oct2013, Vol. 13 Issue 5, p507 

    The article focuses on the challenges associated with the diagnosis and treatment of invasive fungal infections in the Great Britain. It mentions that Invasive aspergillosis (IA) and Invasive candidiasis (IC) are the two most common infections caused due to the fungal pathogens. It reveals that...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics